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Abstract
Introduction: The homeobox-containing transcription factor muscle segment homeobox 2 (Msx2) plays an
important role in mammary gland development. However, the clinical implications of Msx2 expression in breast
cancer are unclear. The aims of this study were to investigate the potential clinical value of Msx2 as a breast cancer
biomarker and to clarify its functional role in vitro.
Methods: Msx2 gene expression was first examined in a well-validated breast cancer transcriptomic dataset of 295
patients. Msx2 protein expression was then evaluated by immunohistochemistry in a tissue microarray (TMA)
containing 281 invasive breast tumours. Finally, to assess the functional role of Msx2 in vitro, Msx2 was ectopically
expressed in a highly invasive breast tumour cell line (MDA-MB-231) and an immortalised breast cell line (MCF10a),
and these cell lines were examined for changes in growth rate, cell death and cell signalling.
Results: Examination of Msx2 mRNA expression in a breast cancer transcriptomic dataset demonstrated that
increased levels of Msx2 were associated with good prognosis (P = 0.011). Evaluation of Msx2 protein expression
on a TMA revealed that Msx2 was detectable in both tumour cell nuclei and cytoplasm. Cytoplasmic Msx2
expression was associated with low grade tumours (P = 0.012) and Ki67 negativity (P = 0.018). Nuclear Msx2
correlated with low-grade tumours (P = 0.015), estrogen receptor positivity (P = 0.038), low Ki67 (P = 0.005) and
high cyclin D1 expression (P = 0.037). Increased cytoplasmic Msx2 expression was associated with a prolonged
breast cancer-specific survival (P = 0.049), recurrence-free survival (P = 0.029) and overall survival (P = 0.019).
Ectopic expression of Msx2 in breast cell lines resulted in radically decreased cell viability mediated by induction of
cell death via apoptosis. Further analysis of Msx2-expressing cells revealed increased levels of p21 and
phosphorylated extracellular signal-regulated kinase (ERK) and decreased levels of Survivin and the ‘split ends’
(SPEN) protein family member RBM15.
Conclusions: We conclude that increased Msx2 expression results in improved outcome for breast cancer patients,
possibly by increasing the likelihood of tumour cell death by apoptosis.
Introduction
Homeobox genes are important during embryonic
development, where they function to control cell fate
and positioning, thereby regulating the morphological
development of several organs, including skeletal struc-
tures, the heart, teeth, eyes and mammary glands [1-6].
The homeobox family of transcription factors were ori-
ginally isolated from Drosophila and contain a common
61-amino acid domain, known as the homeodomain,
which can directly bind DNA and regulate gene tran-
scription [7]. Mutations in the muscle segment homeo-
box 2 (Msx2) homeodomain which cause loss or gain of
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defects [8,9]. Msx2 function can also be affected by sub-
cellular localisation and protein-protein interactions [7].
Within the mammary gland, homeobox genes are
thought to be involved in assimilating systemic signals
into the precise local interactions required for correct
morphogenesis [7,10]. During puberty, the core epithe-
lial structure of the mammary tree is established
through the invasion of the terminal end buds from the
nipple into the surrounding fat pad [11]. Apoptosis
plays an important role in this process, and the level of
apoptosis in the mouse pubertal mammary gland is
higher than at any other stage of development [12]. In
the mouse, Msx2 is expressed during pubertal develop-
ment and early pregnancy, downregulated during late
pregnancy and lactation, and reexpressed during involu-
tion [3,13]. Msx2 expression is stimulated by both estra-
diol and progesterone, and the role of progesterone in
promoting branching morphogenesis in the mouse
mammary gland is thought to be mediated partially
through Msx2 [14]. However, one of the few studies on
Msx2 expression in human breast tissues reported a
complicated regulation of Msx2 by steroid hormones:
Msx2 could be either increased or decreased by steroid
hormone treatment, depending on the estrogen/proges-
terone receptor (ER/PR) status and whether the breast
tissue sample was normal or malignant [15].
Given its widespread regulatory role in growth and
development, it would not be surprising to find that
Msx2 is involved in tumourigenic processes. Indeed, stu-
dies in various cell line models have suggested that
increased expression of Msx2 can induce neoplastic
transformation and epithelial-to-mesenchymal transition
(EMT) [16,17]. However, Barnes et al.f o u n dt h a tM s x 2
repressed the activity of the prometastatic bone sialo-
protein (BSP) in breast cancer cell lines [18], casting
doubt on a proinvasive role for Msx2, as BSP is asso-
ciated with poor outcome in breast cancer [19]. A role
has also been proposed for Msx2 in the regulation of
cell death. A recent study of Sonic hedgehog-1 (Shh)-
knockout mice [2] found that expression of Msx1 and
Msx2 was increased, and this was partially responsible
for the massive apoptosis and severe limb defects seen
in the Shh-null phenotype. Furthermore, ectopic expres-
sion of Msx2 can induce apoptosis in pluripotent mur-
ine embryonic carcinoma cells [20], and cranial neural
crest-derived cells [5]. This effect on cell death can also
be induced by expression of the bone morphogenetic
protein (BMP) family: Msx2 and p21 are induced follow-
ing BMP4 treatment, and both molecules are necessary
for BMP4-mediated cell death to occur in several cell
types [21,22].
Large-scale clinical studies of Msx2 expression in can-
cer are few in number. A study of 32 pancreatic
adenocarcinomas demonstrated an association between
Msx2 expression and high tumour grade and vascular
invasion [17]. The only study of Msx2 in breast tumours
to date involved four invasive ductal carcinomas and
found that Msx2 expression was increased in infiltrating
compared to noninfiltrating cells [16]. The prognostic
influence of Msx2 expression has not been investigated
in a large cohort of breast cancer patients. The aim of
this study was to investigate Msx2 expression as a prog-
nostic biomarker in breast cancer. We also sought to
clarify the in vitro functional role of Msx2. Our findings
indicate that increased expression of both Msx2 mRNA
and protein are associated with improved outcome in
breast cancer. We also found that ectopic expression of
Msx2 in breast cell lines leads to induction of apoptosis
and radically decreased cell viability. These data suggest
that increased Msx2 results in improved outcome for
breast cancer patients, possibly by increasing the likeli-
hood of tumour cell death by apoptosis.
Materials and methods
Statistical analysis of DNA microarray data
Relevant gene expression and clinical data relating to
295 patients with breast cancer [23] were downloaded
from Rosetta Inpharmatics Inc. [24]. The log ratios of
gene expression values were used without modification
and classified using a previously published method [25].
Tumour samples were classified by first separating into
quartiles according to mRNA expression. Adjacent
groups with significant overlap of Kaplan-Meier survival
curves were combined, and the survival curves of the
resulting two groups were compared using the log-rank
test. The c
2 test and Fisher’se x a c tt e s tw e r eu s e df o r
relating mRNA levels to clinicopathological variables.
Patients
The tissue microarray (TMA) used in this study was
derived from a reference cohort of 512 consecutive inva-
sive breast cancer cases diagnosed at Malmö University
Hospital, Sweden, between 1988 and 1992, and has been
previously described [26,27]. From the original cohort of
512 patients, samples were available from 281 patients
for analysis of Msx2 protein expression (this reduced
number was primarily due to core loss). Patient and
tumour characteristics of the available and missing
cohorts are outlined in Additional file 1. The study has
been approved by the Ethics Committee at Lund
University.
TMA construction
The TMA was constructed as previously described [25].
Briefly, two 0.6-mm tissue cores were extracted from
each donor block using an automated tissue arrayer
(MTA-27; Beecher Inc., Sun Prairie, WI, USA) and
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analysis results, a cell pellet array (CPA) was con-
structed as previously described [27] using formalin-
fixed, paraffin-embedded (FFPE) breast cell lines.
Cell culture
All cell lines (MCF-7, T47 D, BT474, ZR75-1, MDA-
MB-231, and SKBR3) were purchased from the Eur-
opean Collection of Cell Cultures (Wiltshire, UK),
except for the MCF10a cell line, which was a gift from
D r .G e e r tB e r x ,U n i v e r s i t yo fG h e n t ,B e l g i u m ,a n dt h e
Hs578t isogenic cell line series (Hs578t P and i8) [28],
which was a gift from Dr. Susan McDonnell, University
College Dublin. All cell lines were maintained as pre-
viously described [27].
Western blot analysis
For analysis of cell lines, protein was extracted as pre-
viously described [27]. Lysates were separated by redu-
cing sodium dodecyl sulphate-polymerase gel
electrophoresis (SDS-PAGE), transferred to polyvinyli-
dene fluoride (PVDF), and immunoblotted using antibo-
dies against Msx2 (clone 2E12, 1:1,000; Abcam,
Cambridge, UK), extracellular signal-regulated kinase
(ERK) (1:1,000; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), p-ERK (1:1,000; Santa Cruz Biotechnology),
p21 (1:1,000; BD Biosciences, Franklin Lakes, NJ, USA),
Survivin (1:100; Santa Cruz Biotechnology), cyclin D1
(1:1,000; Santa Cruz Biotechnology), DLX5 (clone 3B11;
1:1,000; Abnova, Taipei, Taiwan), Twist (1:1,000; Santa
Cruz Biotechnology), and Smad4 (1:1,000; Cell Signaling,
Danvers, MA, USA). Membranes were stripped and
reprobed with anti-b-actin (1:5,000 dilution; Abcam) as
a loading control.
Immunohistochemistry
TMA and CPA sections (4 μm) were rehydrated in des-
cending gradient alcohols. Heat-mediated antigen retrie-
val was performed using 10 mM sodium citrate buffer
(pH 6) in a PT module (LabVision; Thermo-Fisher
Scientific, Fremont, CA, USA) for 15 min at 95 °C, fol-
lowed by immunohistochemistry (IHC) in a Lab Vision
Autostainer 360 (LabVision, Fremont, CA, USA) for
Msx2 (clone 2E12; 1:25; Abcam) or in the Ventana
Benchmark system (Ventana Medical Systems Inc., Oro
Valley, AZ) using prediluted antibodies to estrogen
receptor (clone 6F11; Ventana Medical Systems Inc.),
progesterone receptor (clone 16; Ventana Medical Sys-
tems Inc.) and Her2 (Pathway, Clone CB-11, Ventana
Medical Systems) or in the Dako Techmate 500 system
(Dako, Glostrup, Denmark) for Ki-67 (M7240, 1:200;
Dako) and cyclin D1 (clone DSC-6, 1:100; Dako). A
mouse IgG2a isotype control (Abcam) was used to eval-
uate Msx2 antibody specificity.
Slides were scanned at ×20 magnification using a
ScanScopeXT slide scanner (Aperio Technologies, Vista,
CA, USA). Tumour samples were evaluated by two
independent observers (RH and FL) and scored for
Msx2 staining intensity in both the cytoplasmic and
nuclear compartments on a scale of 0 to 3, where 0 is
negative, 1 is weakly positive, 2 is medium positive and
3 is strongly positive. Nuclear staining for Msx2 was
found to be relatively homogeneous within tumour sam-
ples, and thus the percentage of nuclear staining was
not included in the scoring system. The mean value of
both scores for each patient was used for statistical ana-
lysis. ER, PR, HER2 and Ki-67 were assessed as pre-
viously described [29].
To control for the subjectivity inherent in the manual
scoring process, we utilised a co-localisation image ana-
lysis algorithm (Aperio Technologies) to further exam-
ine Msx2 localisation and expression. This algorithm
classifies each pixel as either blue (negative nuclear),
blue and brown (positive nuclear), or brown (positive
cytoplasmic). The average positive pixel intensities of
3,3’-diaminobenzidine (DAB) staining in the cytoplasm
and nuclei were used for statistical analysis, divided at
the 50th percentile.
Statistical analysis of TMA data
The c
2 test and Fisher’s exact test were used to evaluate
associations between Msx2 expression and clinicopatho-
logical characteristics. Kaplan-Meier plots were used for
survival analysis, and the log-rank test was used to com-
pare curves separated according to Msx2 expression. Cox
proportional hazards regression was used to estimate
hazard ratios (HR). All calculations were carried out
using SPSS version 15 (SPSS Inc., Chicago, IL, USA).
Lentiviral overexpression of Msx2
Human embryonic kidney (HEK)-293t cells, at ~60-70%
confluence, were transfected using a calcium phosphate
transfection method with an LLCIEP vector (Trono
Laboratory, Lausanne, Switzerland) with no insert (EV)
or containing full-length Msx2 with a V5 tag (MSX2),
together with packaging and envelope plasmids
(PSPAX2 and PMD2G; Trono Laboratory). The media
were refreshed after 6-8 hr and, after a further 48 hr,
the viral supernatant was removed and filtered through
a 0.45-μm low-protein binding filter (Millipore, Billerica,
MA, USA). This was added to ~50% confluent MDA-
MB-231 or MCF10a cells at a 1:3 dilution with fresh
media, along with 8 μg/ml polybrene. MCF10a cells
were centrifuged at 300 × g for 1 hr at 30°C following
addition of the viral supernatant. Media were refreshed
after 24 hr. The transduction efficiency was estimated at
>95% using immunofluorescence microscopy for Msx2
expression.
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Cells growing on chamber slides (Nunc, Roskilde, Den-
mark) were fixed with 3.7% paraformaldehyde for 20
min, permeabilised with 0.5% Triton-X 100 for 10 min,
and labelled immunofluorescently using an anti-Msx2
mouse monoclonal antibody (Abcam), followed by incu-
bation with a rhodamine-coupled secondary antibody
(Abcam) and 4’,6-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich, Dorset, UK). Images were obtained
using a Zeiss LSM-510-Meta confocal microscope.
MTT proliferation assay
Cellular proliferation was measured using an MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) colorimetric assay over a period of 5 days. Cells
were seeded at a density of 2,000 cells/well in 96-well
plates, with one plate measured every day for 5 days.
Cells were incubated with MTT reagent (5 mg/ml) for 4
hr, solubilised in dimethyl sulfoxide, and the absorbance
at 570 nm was measured.
Colony formation assay
Cells were seeded at a density of 500 cells/well in a six-
well plate. Plates were incubated for 3 weeks with media
changed weekly. Cells were fixed for 15 min in 10%
neutral-buffered formalin and stained with 0.25% crystal
violet solution. Colonies were counted by eye, with three
wells counted per cell line in each replicate experiment.
Apoptosis assay
The Caspase-Glo 3/7 kit (Promega, Madison, WI, USA)
was used to determine levels of apoptosis in cell lines.
Cells were seeded in two 96-well plates at 5,000 cells/
well and allowed to grow for 2 days. Media were
removed from one plate, replaced with Caspase-Glo
working solution in a 1:1 dilution to normal media, left
at room temperature for 1 hr, and read using a lumines-
cent plate reader (GloMax Multi Detection System, Pro-
mega). The cells on the second plate were trypsinized
and counted to normalize the luminescent signal to cell
number.
Cell cycle analysis
Cells at ~60-70% confluence were harvested and washed
in ice-cold phosphate-buffered saline (PBS) before fixa-
tion for 1 hr in ice-cold 70% ethanol in PBS. Cells were
collected by centrifugation, washed in PBS and recentri-
fuged before resuspension in 1 ml of ice-cold PBS con-
taining 0.4 mg/ml propidium iodide (PI). Cells were left
for 30 min on ice prior to flow cytometry analysis on a
Coulter Epic XL flow cytometer (Beckman Coulter Inc.,
Brea, CA, USA), to measure the PI uptake and thus the
DNA content of the cells.
Results
Msx2 mRNA expression is associated with good prognosis
in a DNA microarray dataset
Expression levels of Msx2 mRNA were analysed in a
publicly available DNA microarray dataset derived from
295 primary invasive breast tumours [23]. Using a pre-
viously described method [25], 74 tumours were classi-
fied as expressing low levels of Msx2 mRNA, and 221
tumours were classified as expressing high levels of
Msx2 mRNA, based on the log ratios of gene expression
values. Survival analysis of these tumours revealed that
increased expression of Msx2 mRNA was associated
with good prognosis (P = 0.011) (Figure 1). Univariate
Cox regression analysis of Msx2 mRNA expression as a
continuous variable supported this association with
favourable outcome (HR 0.47; 95% CI 0.24-0.95; P =
0.035). Associations between Msx2 mRNA expression
and commonly used clinical biomarkers were also exam-
ined (Table 1). Increased Msx2 mRNA expression corre-
lated with ER-positive (P < 0.001) and low-grade (P =
0.003) tumours; moreover, it was associated with good
prognosis according to the 70-gene signature defined by
van’t Veer et al. [30] (P < 0.001). In relation to breast
cancer molecular subtypes described by Sorlie et al.
[31], Msx2 mRNA expression was particularly low in
the basal subtype and high in the luminal B and Her2
subtypes of breast cancer (P = 0.001).
Msx2 protein expression in primary breast tumours
The specificity of the Msx2 antibody was validated first
by Western blot analysis on a panel of breast cancer cell
lines (Figure 2a) and second by IHC in FFPE breast can-
cer cell lines (Figure 2b). High Msx2 expression was
detected by Western blot analysis in MCF7, T47 D,
SKBR3 and ZR75-1 cell lines, with low expression seen
in BT474 cells and no detectable expression in MDA-
MB231, Hs578t, Hs578t-i8 and MCF10a cell lines. This
expression pattern appears for the most part to correlate
with ER status, apart from the high expression of Msx2
seen in the ER-negative cell line SK-BR3. MCF7 and
MCF10a cell lines were used as positive and negative
controls, respectively, for all further IHC procedures.
Msx2 protein expression was assessed using IHC in a
breast cancer TMA constructed from a cohort of 512
patients. Owing to core loss, it was possible to evaluate
Msx2 protein expression in 281 tumours (55%) of the
512 tumours represented on the TMA. To evaluate our
study for any potential selection bias, baseline clinico-
pathological characteristics from both the evaluated or
‘Msx2 known’ cohort (n = 281) and the unevaluated or
‘Msx2 unknown’ cohort (n =2 3 1 )a r ep r e s e n t e di n
Additional file 1. No difference was seen in the expres-
sion of any variable between either cohort.
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of Msx2 protein was evident, with levels of Msx2 in
these subcellular compartments being scored sepa-
rately (Figure 2c). Staining in each compartment was
scored on a scale from 0 to 3 on the basis of staining
intensity. To divide the tumours into two relatively
equal-sized groups, high cytoplasmic Msx2 was
defined as a staining intensity ≥2, and high nuclear
Msx2 was defined as a staining intensity ≥1. On the
basis of this analysis, 168 tumours (59.8%) were classi-
fied as expressing low levels of cytoplasmic Msx2, and
113 tumours (40.2%) were classified as expressing high
cytoplasmic Msx2. Similarly, 122 tumours (43.4%)
were classified as expressing low nuclear Msx2, and
159 tumours (56.6%) were classified as expressing high
nuclear Msx2.
Associations between nuclear and cytoplasmic Msx2
protein expression and a number of well-established
clinicopathological variables were then investigated
(Table 2). Cytoplasmic Msx2 expression was associated
with low-grade tumours (P = 0.012) and low expression
of Ki67 (proliferation-related Ki-67 antigen) (P =0 . 0 1 8 ) .
Nuclear Msx2 expression was associated with low-grade
(P = 0.015), ER-positive (P = 0.038) tumours, low Ki67
expression (P = 0.005), and increased nuclear cyclin D1
expression (P = 0.037).
Increased Msx2 protein expression is associated with
prolonged patient survival
The relationship between Msx2 protein expression and
survival was then examined. In agreement with our pre-
vious findings, cytoplasmic Msx2 was associated with
longer breast cancer-specific survival (BCSS) (P =
0.049), recurrence-free survival (RFS) (P = 0.029), and
overall survival (OS) (P = 0.019) (Figure 3). In contrast,
nuclear Msx2 expression was not associated with out-
come at any endpoint: BCSS (P =0 . 2 2 0 ) ,R F S( P =
0.439) or OS (P = 0.123). Univariate Cox regression ana-
lysis confirmed that increased cytoplasmic Msx2 expres-
sion was associated with an extended BCSS (HR 0.54;
95% CI 0.29-1.01; P = 0.053), RFS (HR 0.57; 95% CI
0.35-0.92; P = 0.021) and OS (HR 0.69; 95% CI 0.49-
0.97; P = 0.031). To compare the prognostic impact of
Msx2 with well-established clinical variables, a multi-
variate Cox regression analysis was carried out using OS
as an endpoint (Table 3). Cytoplasmic Msx2 expression
was an independent predictor of prolonged OS (HR
0.58; 95% CI 0.36-0.93; P =0 . 0 2 3 ) ,a l o n gw i t ht u m o u r
grade (HR 1.78; 95% CI 1.06-2.99; P = 0.028) and nodal
Table 1 Analysis of Msx2 expression at the mRNA level
within the van de Vijver dataset
a
Variable Van de Vijver data set (n = 295)
Low Msx2
(n = 74)
High Msx2
(n = 221)
P value
Age 0.592
≤50 65 (87.8) 199 (90)
> 50 9 (12.2) 22 (10)
Tumour size 0.297
≤2 cm 35 (47.3) 120 (54.3)
> 2 cm 39 (52.7) 101 (45.7)
Nodal status 0.056
Negative 45 (60.8) 106 (48)
Positive 29 (39.2) 115 (52)
Tumour grade 0.003
Low 12 (16.2) 63 (28.5)
Intermediate 20 (27) 81 (36.7)
High 42 (56.8) 77 (34.8)
ER status <0.001
Negative 39 (52.7) 30 (13.6)
Positive 35 (47.3) 191 (86.4)
Tumour subtype <0.001*
Normal 7 (9.5) 24 (10.9)
Luminal A 20 (27) 68 (30.8)
Luminal B 11 (14.9) 70 (31.7)
Basal 30 (40.5) 16 (7.2)
Her2 6 (8.1) 43 (19.5)
70-gene signature 0.003
Poor 56 (75.7) 124 (56.1)
Good 18 (24.3) 97 (43.9)
aER, estrogen receptor; *Fisher’s exact test;, otherwise, c2 test.
Figure 1 Analysis of muscle segment homeobox 2 (Msx2)
expression at the mRNA level. Kaplan-Meier estimates of overall
survival (OS) stratified by Msx2 expression within the Van de Vijver
dataset of 295 breast tumours.
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Cox regression analysis of nuclear Msx2 showed no
association with outcome (HR 0.78; 95% CI 0.56-1.07;
P = 0.124).
To control for subjectivity in the manual scoring pro-
cess, we used a co-localisation algorithm (Aperio) to
impartially examine Msx2 expression and localisation.
We found a strong correlation between automated and
manual scores (Spearman’s r = 0.745; P < 0.001). Using
the automated data, cytoplasmic Msx2 expression was
associated with overall survival (P = 0.008), whereas
nuclear Msx2 expression was not (P = 0.097), in agree-
ment with manual scoring data (Additional file 2).
Msx2 induces cell death by apoptosis in both
transformed and immortalized breast cell lines
Having shown that Msx2 expression correlates with good
prognosis in breast tumours, we proceeded to examine
the role of Msx2 in vitro. Cells suitable for Msx2 overex-
pression were determined by Western blot analysis
(Figure 2a). MDA-MB-231, Hs578t, and MCF10a cells all
had undetectable levels of Msx2 protein. We chose a
highly invasive breast cancer cell line (MDA-MB-231)
and an immortalized mammary epithelial cell line
(MCF10a) for our study. Ectopic Msx2 was overexpressed
in these cell lines, and expression was verified by
Western blot analysis, which showed that both the
MDA-MB-231-Msx2 (designated MDA-Msx2) and
MCF10a-Msx2 cell lines displayed high levels of Msx2
protein compared to the corresponding empty vector
(EV) controls (Figure 4a). We also examined these cell
lines by immunofluorescence microscopy using a fluores-
cently tagged secondary antibody (Figure 4b). This
revealed high levels of Msx2 in both MDA-Msx2 and
MCF10a-Msx2 cell lines, the expression of which was
predominantly nuclear and perinuclear.
Figure 2 Validation of Msx2 antibody specificity. (a) Western blot analysis of breast cell lines for Msx2 expression, showing Msx2 migrating at
approximately 37 kDa. b-actin levels were used to evaluate protein loading. (b) Immunohistochemical staining for Msx2 on formalin-fixed, paraffin-
embedded (FFPE) breast cell lines (×20 magnification). (c) Immunohistochemical staining for Msx2 on breast tumour tissue microarray (TMA) cores,
showing examples of tumours with scores from 0 to 3 for nuclear and cytoplasmic staining (×20 magnification; scale bar represents 10 μm).
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a
Variable Cytoplasmic Msx2 Nuclear Msx2
Low Msx2
(n = 168)
High Msx2
(n = 113)
P value Low Msx2
(n = 122)
High Msx2
(n = 159)
P value
Age
Median (range) 66 (35-96) 64 (36-89) 65 (35-96) 65.5 (35-91)
≤50 23 (13.7) 14 (12.4) 0.752 19 (15.6) 18 (11.3) 0.296
>50 145 (86.3) 99 (87.6) 103 (84.4) 141 (88.7)
Tumour size
Median (range) 18 (0-100) 16 (1-100) 19 (0-100) 15.5 (1-100)
≤2 cm 105 (62.5) 75 (66.4) 0.507 74 (60.7) 106 (66.7) 0.298
>2 cm 63 (37.5) 38 (33.6) 48 (39.3) 53 (33.3)
Histological type
Ductal 115 (75.7) 75 (69.4) 0.157* 80 (72.7) 110 (73.3) 0.715*
Lobular 19 (12.5) 22 (20.4) 19 (17.3) 22 (14.7)
Tubular 9 (5.9) 8 (7.4) 5 (4.5) 12 (8)
Medullary 5 3.3) 0 3 (2.7) 2 (1.3)
Mucinous 4 (2.6) 3 (2.8) 3 (2.7) 4 (2.7)
Unknown 16 5 12 9
Nodal status
Negative 89 (59.3) 69 (69) 0.121 66 (61.1) 92 (64.8) 0.550
Positive 61 (40.7) 31 (31) 42 (38.9) 50 (35.2)
Unknown 18 13 14 17
Tumour grade
I 34 (20.4) 35 (31) 0.012 20 (16.4) 49 (31) 0.015
II 66 (39.5) 51 (45.1) 54 (44.3) 63 (39.9)
III 67 (40.1) 27 (23.9) 48 (39.3) 46 (29.1)
Unknown 1 0 0 1
ER status
Negative 23 (14.1) 16 (14.7) 0.896 23 (19.3) 16 (10.5) 0.038
Positive 140 (85.9) 93 (85.3) 96 (80.7) 137 (89.5)
Unknown 5 4 3 6
PR status
Negative 47 (36.4) 38 (40.9) 0.503 41 (40.6) 44 (36.4) 0.518
Positive 82 (63.6) 55 (59.1) 60 (59.4) 77 (63.6)
Unknown 39 20 21 38
Ki 67 (%)
<10% 56 (34.1) 52 (48.6) 0.018 35 (30.2) 73 (47.1) 0.005
>10% 108 (65.9) 55 (51.4) 81 (69.8) 82 (52.9)
Unknown 4 6 6 4
VEGF (%)
Low (0-2+) 92 (78) 77 (86.5) 0.116 76 (83.5) 93 (80.2) 0.537
High (3) 26 (22) 12 (13.5) 15 (16.5) 23 (19.8)
Unknown 50 24 31 43
Her2 (%)
Low (0-2) 141 (89.2) 95 (92.2) 0.422 100 (89.3) 136 (91.3) 0.589
High (3) 17 (10.8) 8 (7.8) 12 (10.7) 13 (8.7)
Unknown 10 10 10 10
Cyclin D1 (%)
Low (0-1%) 20 (12.5) 17 (15.7) 0.706 21 (17.9) 16 (10.6) 0.037
Med (2-25%) 109 (68.1) 69 (63.9) 80 (68.4) 98 (64.9)
High (>25%) 31 (19.4) 22 (20.4) 16 (13.7) 37 (24.5)
Unknown 8 5 5 8
aMsx2, muscle segment homeobox 2; ER, estrogen receptor; PR, progesterone receptor; Ki67, proliferation-related Ki-67 antigen; VEGF, vascular endothelial
growth factor; Her2, human epidermal growth factor 2; *Fisher’s exact test;, otherwise, c2 test.
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appeared to be undergoing cell death, whereas the EV-
transduced cells grew unperturbed (Figure 4c); thus, the
effect of Msx2 overexpression on cell growth, ancho-
rage-independent growth, and cell death was examined
(Figure 5). A significant reduction in growth rates, as
measured by MTT assay over a period of 5 days, was
observed between EV-transduced cells and their Msx2-
overexpressing counterparts, namely, MDA-Msx2
(P = 0.005) and MCF10a-Msx2 (P =0 . 0 2 3 )( F i g u r e5 a ) .
Clonogenic assays also revealed a dramatic decrease in
cell viability in both MSX2-expressing cell lines
(P < 0.001 for both) (Figure 5b). The mechanism of cel-
lular death was then investigated using a luminescence-
Figure 3 Kaplan-Meier estimates of survival in 281 breast tumours on a TMA. (a) Breast cancer-specific survival (BCSS), (b) recurrence-free
survival (RFS), (c) OS stratified according to cytoplasmic Msx2 expression. (d) BCSS, (e) RFS, and (f) OS stratified according to nuclear Msx2
expression.
Table 3 Cox regression analysis of overall survival in the entire patient cohort
a
Entire cohort (n = 281)
Univariate Multivariate*
Prognostic factor HR (95% CI) P value HR (95% CI) P value
Cytoplasmic Msx2 (high vs. low, ref) 0.69 0.49-0.97 0.031 0.58 0.36-0.93 0.023
Age (continuous) 1.06 1.05-1.07 <0.001 1.05 1.03-1.07 <0.001
Tumour size (continuous) 1.01 1.00-1.01 <0.001 1.01 1.00-1.02 0.006
Tumour grade (3 vs. 0-2, ref) 2.09 1.63-2.67 <0.001 1.78 1.06-2.99 0.028
Nodal status (pos vs. neg, ref) 3.18 2.43-4.16 <0.001 3.06 1.95-4.80 <0.001
ER (pos vs. neg, ref) 0.73 0.52-1.02 0.062 0.92 0.38-2.21 0.855
PR (pos vs. neg, ref) 0.61 0.46-0.81 0.001 0.68 0.41-1.13 0.140
Her2 (3 vs. 0-2, ref) 0.77 0.49-1.22 0.270 0.63 0.23-1.69 0.355
Ki-67 (>10% vs. <10%, ref) 1.31 1.01-1.71 0.044 1.15 0.67-1.97 0.610
aMsx2, muscle segment homeobox 2; ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor 2; Ki67, proliferation-related Ki-67
antigen. *Adjusted for all other variables in the table; ref, referent group.
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Page 8 of 14based assay (Caspase-Glo 3/7), which detects apoptosis
by measuring levels of caspase-3 and -7 within cells.
This revealed a significant increase in caspase activity in
both MDA-Msx2 (P < 0.001) and MCF10a-Msx2
(P = 0.003) cell lines relative to controls, indicating that
the mode of cell death was apoptosis (Figure 5c). The
proportion of cells in sub-G1, as measured by flow cyto-
metric analysis, was also significantly higher in MDA-
Msx2 (P < 0.001) and MCF10a-Msx2 (P <0 . 0 0 1 )c e l l
lines compared to controls (Figure 5d). Taken together,
these data indicate that increased levels of Msx2 in
breast cells can lead to induction of cell death by
apoptosis.
Msx2 overexpression in cell line models leads to an
alteration in a number of signalling pathways
To elucidate the mechanism by which Msx2 might
induce apoptosis, the expression of several proteins
involved in cell signalling was examined in the Msx2-
overexpressing and control cells (Figure 4a). We first
examined ERK activation and found that ectopic Msx2
expression induced activation of ERK by phosphorylation
Figure 4 Characterisation of Msx2-overexpressing breast cell lines. (a) Light microscopic images of MDA-MB-231 and MCF10a cell lines,
transduced with EV or Msx2 expression vector, showing increased cell death in Msx2-overexpressing cells. (b) Immunofluorescence microscopy
detecting Msx2 localisation in MDA-MB-231 and MCF10a cell lines with ectopic Msx2 expression. Scale bar represents 10 μm. Images are
representative of three experiments. (c) Examination of a number of cell cycle and Msx2-interacting proteins by Western blot analysis in empty
vector and Msx2-overexpressing MDA-MB-231 and MCF10a cell lines. Images are representative of three replicates.
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Page 9 of 14at Tyr204 in both the MDA-Msx2 and MCF10a-Msx2
cell lines compared to EV controls. We proceeded to
look at a number of proteins which regulate cell cycle
and apoptosis and found that the Msx2-overexpressing
cell lines had notably increased levels of the cyclin-
dependent kinase inhibitor p21 (Cip1) and decreased
levels of the apoptotic inhibitor Survivin (BIRC5). Levels
of cyclin D1 protein were unaffected by ectopic Msx2
expression in these cell lines.
W en e x tf o c u s e do np r o t e i n si n v o l v e di nt r a n s c r i p -
tional regulation which may interact with Msx2 and
affect its activity as a transcription factor. Levels of the
homeobox transcription factor, DLX5, were unaffected
by Msx2 overexpression, as was the transcriptional regu-
lator Smad4. Msx2 is known to interact with the SPEN
(a derivation of ‘split ends’ in Drosophila) family of tran-
scriptional regulators [7,32], and we found that levels of
RBM15 (RNA-binding motif protein 15), a member of
the SPEN family, were decreased in Msx2-overexpres-
sing cells. Finally, we looked at expression of Twist, a
transcription factor known to promote EMT, which has
previously been shown to be induced by Msx2 [17].
Twist was expressed in the transformed MDA-MB-231
cell line, but not in the immortalized MCF10a cell line.
We saw no change in Twist expression between control
and Msx2-overexpressing cells.
Msx2 mRNA expression correlates with expression of cell
cycle proteins in tumour samples
To correlate our in vitro cell line data with the clinical
situation, we examined the expression of a number of
cell survival, cell cycle and Msx2-interacting genes
within the previously described Van de Vijver dataset
[23] (Table 4). In relation to cell survival, high levels of
Msx2 mRNA were associated with low mRNA levels of
the apoptotic inhibitor Survivin (P < 0.001). With regard
to cell cycle, increased Msx2 mRNA expression was
associated with high cyclin D1 (P < 0.001) and low
levels of the cyclins A1 (P =0 . 0 3 7 ) ,A 2( P =0 . 0 0 7 ) ,B 2
(P = 0.014), and E1 (P = 0.003). We also examined the
Msx2-interacting protein, Dlx5, which was associated
with poor prognosis (P = 0.032) but did not significantly
correlate with Msx2 expression (P = 0.077). In addition,
we found that high Msx2 expression was associated
with increased levels of BMP4 (P = 0.017), which has
previously been shown to induce Msx2 expression [21].
BMP4 alone was associated with good prognosis (P <
0.001). Expression data on p21 or RBM15 was not avail-
able within this dataset.
Discussion
The objective of this study was to clarify the role of
Msx2 in breast cancer. Previous studies have postulated
Figure 5 Functional analysis of Msx2-overexpressing breast cell lines. (a) Measurement of cell proliferation rates by MTT assay. Significance
was determined by comparing the slopes of the lines of best fit. (b) Measurement of colony forming ability of cellsby clonogenic assays. (c)
Measurement of caspase-3 and -7 activation as an indicator of apoptosis. Values are relative to control levels. (d) Cell cycle analysis by propidium
iodide staining. Values represent the percentage of cells within sub-G1 gate. For all assays, values denote the mean readings of three
independent replicates (n = 3 within each experiment), and error bars represent SD within replicate experiments. Unpaired, two-tailed Student’s
t-tests were used to determine the significance of difference between samples.
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Page 10 of 14a role for Msx2 in the advancement of the invasive phe-
notype in breast cancer [16]. However, it has become
clear from our analysis of two independent patient
cohorts that increased Msx2 mRNA and protein expres-
sion is associated with improved outcome in breast can-
cer. Interestingly, in the TMA-based study, cytoplasmic
as opposed to nuclear MSX2 expression was more sig-
nificant in relation to improved survival, suggesting that
the DNA-binding activity of Msx2 may not be the main
reason for the beneficial effects of Msx2 overexpression.
However, some factors which were not associated with
cytoplasmic Msx2, such as ER status and cyclin D1,
were associated with nuclear Msx2, indicating that
Msx2 may have some additional activity upon transloca-
tion to the nucleus.
Our hypothesis that Msx2 is a good prognostic marker
in breast cancer was further supported by the subse-
quent in vitro investigations, when we overexpressed
Msx2 in both an immortalized mammary epithelial cell
line (MCF10a) and an invasive breast cancer cell line
(MDA-MB-231). In both cell lines, a drastic reduction
in cell viability, apparently due to induction of apoptosis,
was observed. Investigation of how this apoptosis might
occur through dissection of signalling pathways showed
that ERK activation was increased in Msx2-overexpres-
sing cells. Although ERK activation is known to stimu-
late cell growth in many situations, it can also induce
apoptosis in certain cases, depending on the down-
stream signals activated [33]. We also found an increase
in p21 expression concurrent with Msx2 in these cell
lines. Previous studies of BMP4-induced apoptosis in
various cell types [21,22] have shown that both Msx2
and p21 are induced following BMP4 treatment. Inhibi-
tion of either molecule alone was sufficient to block cell
death, suggesting that both are needed for apoptosis to
occur and that they may be part of the same apoptotic
cascade. Indeed, the BMP pathway may be involved in
modulating the effect of Msx2 expression in breast can-
cer: analysis of BMP4 expression in 295 tumours from a
transcriptomic dataset revealed that Msx2 is associated
with high levels of BMP4 in breast tumours, and BMP4
itself was associated with improved patient outcome
within this dataset.
In-depth analysis of cell cycle machinery within Msx2-
overexpressing cells showed that levels of the apoptosis
inhibitor Survivin were decreased, possibly leaving these
cells susceptible to apoptosis. Survivin is a significant
predictor of poor prognosis in breast cancer [34].
Although we saw no change in levels of cyclin D1 fol-
lowing Msx2 overexpression in vitro, when we examined
the van de Vijver dataset, we found that Msx2 was asso-
ciated with high cyclin D1 and low cyclin A1, A2, B2
and E1. High cyclin D1 is needed for cells to pass the
G1 checkpoint, and it was previously thought to be
associated with increased proliferation and poor clinical
outcome. However, further studies have revealed that
cyclin D1 can be associated with improved outcome in
breast cancer, possibly due to the blocking effects of
p27, which is often increased in parallel with cyclin D1
[35,36]. In this transcriptomic dataset, cyclin D1 was
associated with good prognosis and also with p27
expression (P < 0.001), indicating a possible mechanism
whereby high expression of Msx2 can be linked to cell
cycle arrest. The fact that Msx2 mRNA expression in
these tumours correlates with markers of cell cycle
arrest and apoptosis suggests that the apoptosis which
we observed in vitro may represent a real phenomenon
in breast tumours in vivo. However, further mechanistic
analyses are needed to confirm this hypothesis.
Further analysis of the Msx2-overexpressing cell lines
revealed that levels of the SPEN family member RBM15
were downregulated concurrently with Msx2 overex-
pression. Although very little is known about the phy-
siological role of RBM15, it is closely related to SHARP,
another member of the SPEN family which is known to
Table 4 Association of Msx2 with cell cycle-associated
and Msx2-interacting genes at the mRNA level within the
Van de Vijver dataset
a
Variable Van de Vivjer data set (n = 295)
Low Msx2
(n = 74)
High Msx2
(n = 221)
P value Association with
Prognosis?
Survivin <0.001 Poor**
Low 24 (32.4) 125 (56.6)
High 50 (67.6) 96 (43.4)
Cyclin D1 <0.001 NS
Low
High
32 (43.2)
42 (56.8)
42 (19)
179 (81)
Cyclin A1 0.037 Poor**
Low 49 (66.2) 173 (78.3)
High 25 (33.8) 48 (21.7)
Cyclin A2 0.007 Poor**
Low 27 (36.5) 121 (54.8)
High 47 (63.5) 100 (45.2)
Cyclin B2 0.014 Poor**
Low 28 (37.8) 120 (54.3)
High 46 (62.2) 101 (45.7)
Cyclin E1 0.003 Poor**
Low 46 (62.2) 175 (79.5)
High 28 (37.8) 45 (20.5)
DLX5 0.077 Poor*
Low 50 (67.6) 172 (77.8)
High 24 (32.4) 49 (22.2)
BMP4 0.017 Good**
Low 46 (62.2) 102 (46.2)
High 28 (37.8) 119 (53.8)
aBMP, bone morphogenetic protein; DLX5, distal-less homeobox 5; *P < 0.05
**P < 0.01 (log rank test); otherwise c2 test.
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Page 11 of 14interact with Msx2 [32]. This family of proteins are
characterized by N-terminal RNA recognition motifs
and a conserved SPOC (SPEN paralog and ortholog C-
terminal) domain [37]. The conserved SPOC domain in
both SHARP and RBM15 is known to interact with
SMRT (silencing mediator of retinoid and thyroid hor-
mone receptors) and NCoR (nuclear receptor corepres-
sor) corepressors to mediate transcriptional repression
[38]. RBM15 is also involved in regulating activation of
Notch signalling [39], nuclear export of mRNA [40], and
hematopoietic development and cell fate [41]. Deletion
of RBM15 in mice is embryonic lethal, and conditional
deletion of RBM15 in adult mice results in a reduction
in levels of white blood cells [41]. Although the mechan-
ism of action of RBM15 is unclear, the downregulation
of this protein in Msx2-overexpressing cell lines indi-
cates that RBM15 may interact directly or indirectly
with Msx2 and could mediate, in part, the effects of
Msx2 overexpression.
Perhaps it is the background level of Msx2 interacting
proteins and cofactors that determines the effect of
increased levels of Msx2 in breast tumours. A link with
the ER signalling pathway is also likely, as previous stu-
dies have shown that Msx2 expression can be induced
in breast cancer cell lines and breast explants following
estradiol or progesterone treatment [14,15]. We
observed a correlation between Msx2 expression and ER
status in the majority of the cell lines that were exam-
ined in this study (Figure 2a). The only previous study
of Msx2 overexpression in the breast found an associa-
tion between Msx2 overexpression and induction of
EMT and cellular invasion [16], with no evidence of a
reduction in cell viability or induction of apoptosis.
However, the earlier study used mouse mammary
epithelial cells in which to overexpress Msx2, which
would have a different genetic background to the breast
cell lines used in this study and may therefore have
altered downstream responses to Msx2 overexpression.
This variation in the cellular response to Msx2 indicates
that the context of Msx2 overexpression, as well as its
subcellular localisation and intensity, is an important
factor to consider when examining the role of Msx2 in
breast tumours. In addition, the intracellular milieu of
transcriptional regulators and cofactors may play an
important role in regulating the downstream effects of
Msx2 overexpression.
The varying effect of Msx2 expression in different
tumour types also suggests a cell type-specific effect.
Indeed, Msx2 has been associated with high tumour
grade in pancreatic cancer [17]. Studies in breast cancer
have suggested a link to EMT through induction of
Cripto-1 and the c-Src pathway [16], although this is
contradicted by studies showing that Msx2 downregu-
lates the prometastatic factor BSP [18]. The reasons for
the context-specific effects of Msx2 overexpression are
yet to be explained and may be a result of both changes
in cell lineage and protein localisation. However, the
results from our clinical study make it clear that Msx2
is a marker of good prognosis in human breast cancer,
illustrating the principle that data obtained from in vitro
laboratory work must be supplemented by clinical inves-
tigation to determine the real prognostic value of a
biomarker.
Conclusions
These findings indicate that increased expression of
both Msx2 mRNA and protein are associated with
improved patient outcome in breast cancer. Further-
more, we have shown that ectopic expression of Msx2
in breast cell lines leads to the induction of apoptosis
and radically decreased cell viability. This study suggests
that increased Msx2 results in improved outcome for
breast cancer patients, possibly by increasing the likeli-
hood of tumour cell death by apoptosis.
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